teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. headquartered in wayne, pa, teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
Company profile
Ticker
TFX
Exchange
Website
CEO
Liam Kelly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1902 Federal Road, LLC • Arrow Internacional de Chihuahua, S.A. de C.V. • Arrow Internacional de Mexico, S.A. de C.V. • Arrow International • Arrow International LLC • Arrow Interventional, Inc. • Distribuidora Arrow, S.A. de C.V. • Essential Medical LLC • Hudson Respiratory Care Tecate, S. de R.L. de C.V. • ICOR AB ...
IRS number
231147939
TFX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
29 Aug 24
8-K
Other Events
5 Aug 24
10-Q
2024 Q2
Quarterly report
2 Aug 24
8-K
Teleflex Reports Second Quarter Financial Results and Full Year 2024 Outlook
1 Aug 24
SD
Conflict minerals disclosure
30 May 24
8-K
Departure of Directors or Certain Officers
9 May 24
10-Q
2024 Q1
Quarterly report
3 May 24
8-K
Teleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
2 May 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
Transcripts
TFX
Earnings call transcript
2024 Q2
1 Aug 24
TFX
Earnings call transcript
2024 Q1
2 May 24
TFX
Earnings call transcript
2023 Q4
22 Feb 24
TFX
Earnings call transcript
2023 Q3
2 Nov 23
TFX
Earnings call transcript
2023 Q2
3 Aug 23
TFX
Earnings call transcript
2023 Q2
3 Aug 23
TFX
Earnings call transcript
2023 Q1
4 May 23
TFX
Earnings call transcript
2023 Q1
4 May 23
TFX
Earnings call transcript
2022 Q4
23 Feb 23
TFX
Earnings call transcript
2022 Q3
27 Oct 22
Latest ownership filings
4
John Deren
27 Aug 24
4
STUART A RANDLE
16 Aug 24
144
Notice of proposed sale of securities
16 Aug 24
11-K
Annual report of employee stock purchases
28 Jun 24
4/A
James Winters
20 Jun 24
4/A
Jay White
20 Jun 24
4/A
THOMAS E POWELL
20 Jun 24
4/A
Daniel V. Logue
20 Jun 24
4/A
Liam Kelly
20 Jun 24
4/A
Cameron P Hicks
20 Jun 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Oct 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 238.57 mm | 238.57 mm | 238.57 mm | 238.57 mm | 238.57 mm | 238.57 mm |
Cash burn (monthly) | (no burn) | 1.02 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 3.83 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 234.73 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 230.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2024
96.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 514 |
Opened positions | 95 |
Closed positions | 38 |
Increased positions | 181 |
Reduced positions | 160 |
13F shares | Current |
---|---|
Total value | 8.16 tn |
Total shares | 45.66 mm |
Total puts | 53.90 k |
Total calls | 23.50 k |
Total put/call ratio | 2.3 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price Investment Management | 5.94 mm | $1.25 bn |
Vanguard | 5.57 mm | $1.17 tn |
JHG Janus Henderson | 5.23 mm | $1.10 tn |
BLK BlackRock | 3.88 mm | $816.06 bn |
MS Morgan Stanley | 3.09 mm | $649.41 bn |
STT State Street | 2.04 mm | $428.19 bn |
Wellington Management | 1.30 mm | $272.48 bn |
Geode Capital Management | 1.12 mm | $235.97 bn |
Millennium Management | 1.03 mm | $215.70 bn |
Cooke & Bieler | 912.80 k | $191.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Aug 24 | John Deren | Common Stock | Payment of exercise | Dispose F | No | No | 242.41 | 16 | 3.88 k | 1,977 |
16 Aug 24 | Randle Stuart A | Common Stock | Sell | Dispose S | No | No | 238.93 | 2,674 | 638.90 k | 5,496 |
16 Aug 24 | Randle Stuart A | Common Stock | Option exercise | Acquire M | No | No | 121 | 2,674 | 323.55 k | 8,170 |
16 Aug 24 | Randle Stuart A | Stock Option / Common Stock | Option exercise | Dispose M | No | No | 121 | 2,674 | 323.55 k | 0 |
18 Jun 24 | James Winters | Common Stock | Grant | Acquire A | No | No | 0 | 243 | 0.00 | 3,638 |
18 Jun 24 | James Winters | Stock Option / Common Stock | Grant | Acquire A | No | No | 202.09 | 1,676 | 338.70 k | 1,676 |
7 May 24 | Jaewon Ryu | Common Stock | Grant | Acquire A | No | No | 0 | 649 | 0.00 | 1,176 |
7 May 24 | Jaewon Ryu | Stock Option / Common Stock | Grant | Acquire A | No | No | 201.52 | 1,349 | 271.85 k | 1,349 |
7 May 24 | Neena M Patil | Common Stock | Grant | Acquire A | No | No | 0 | 649 | 0.00 | 1,575 |
7 May 24 | Neena M Patil | Stock Option / Common Stock | Grant | Acquire A | No | No | 201.52 | 1,349 | 271.85 k | 1,349 |
News
Teleflex Announced The Presentation Of Data Supporting The Safety And Efficacy Of Barrigel Rectal Spacer, To Reduce Radiation That Reaches The Rectum During Prostate Cancer Radiation Therapy
17 Oct 24
Where Teleflex Stands With Analysts
14 Oct 24
Truist Securities Maintains Hold on Teleflex, Raises Price Target to $255
14 Oct 24
RBC Capital Maintains Outperform on Teleflex, Raises Price Target to $275
8 Oct 24
(TFX) - Analyzing Teleflex's Short Interest
26 Sep 24
Press releases
New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Efficacy of Barrigel™ Rectal Spacer, the First and Only Sculptable Hyaluronic Acid Rectal Spacer, in Patients Undergoing Radiation Therapy for Prostate Cancer(1-3)
17 Oct 24
Teleflex Announces Third Quarter 2024 Earnings Conference Call Information
17 Oct 24
Teleflex's Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting
26 Sep 24
Teleflex™ Chooses o9's AI-Powered Platform for End-to-End Integrated Business Planning and Supply Chain Management
25 Sep 24
Teleflex to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
22 Aug 24